Connor, Clark & Lunn Investment Management Ltd. Clearside Biomedical, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$22 Billion
Q2 2024

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 09, 2024	BUY	$1.2 - $2.02 $30,489 - $51,324	25,408 New	25,408 $38,000
Q2 2023 Aug 10, 2023	SELL	$0.97 - $1.48 $37,086 - $56,586	-38,234 Reduced 71.07%	15,562 $17,000
Q1 2023 May 09, 2023	SELL	$0.93 - $1.66 $3,011 - $5,375	-3,238 Reduced 5.68%	53,796 $55,000
Q4 2022 Feb 10, 2023	SELL	$1.0 - $1.5 $10,136 - $15,204	-10,136 Reduced 15.09%	57,034 $63,000
Q3 2022 Nov 10, 2022	BUY	$1.08 - $1.83 $18,512 - $31,368	17,141 Added 34.26%	67,170 $76,000
Q2 2022 Aug 05, 2022	SELL	$1.3 - $2.49 $37,989 - $72,765	-29,223 Reduced 36.87%	50,029 $74,000
Q1 2022 May 12, 2022	BUY	$1.35 - $2.88 $106,990 - $228,245	79,252 New	79,252 $181,000

Others Institutions Holding CLSD

# of Institutions

Shares Held

13.4M

Call Options Held

17.6K

Put Options Held

100

View Full List

About Clearside Biomedical, Inc.

Ticker CLSD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,190,700
Market Cap $76.4M
Description
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injec...

More about CLSD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account